C. diff Model Predicts Patients at Risk for Recurrence

Share on Facebook

Researchers have developed a model that accurately predicts which patients are at risk for recurrence of a Clostridium difficile infection, according to research in Clinical Infectious Diseases.

Researchers compared data from two pharmaceutical trials in which fidaxomicin, an antibiotic was compared with vancomycin for C. diff treatment.

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

They subsequently identified four classes of risk factor for the predictive model, including age, number of unformed bowel movements during the previous 24 hours, baseline serum creatinine levels, prior episodes of C. diff and treatment method.

Researchers suggest the model may be useful for clinicians in deciding upon the most effective treatment to prevent recurrence of C. diff infections, something between 20 and 30 percent of those with C. diff experience.

More Articles on Quality:

How a No-Nonsense Hospital CEO Reached the Target of Zero Infections

7 Stories, Studies on Antbiotics

Socioeconomic Status Correlates With Cancer Mortality Rates

© Copyright ASC COMMUNICATIONS 2014. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

New From Becker's Infection Control & Clinical Quality

Physician tests positive for Ebola in New York City: 5 things to know

Read Now


Patient Safety Tools & Resources Database